Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.
Activating mutations in the FLT3 receptor tyrosine kinase occur in 30% of patients with acute myeloid leukemia. Small molecule FLT3 kinase inhibitors show selective antitumor activity in preclinical models. Clinical studies are underway.
Department of Medicine, Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles 90095, USA. csawyers@mednet.ucla.edu
Charles L
CL
Sawyers
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D000068877:Imatinib Mesylate; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D010879:Piperazines / Q000494:pharmacology; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000494:pharmacology; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors*; D051941:fms-Like Tyrosine Kinase 3
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011518:Proto-Oncogene Proteins; D011743:Pyrimidines; D011956:Receptors, Cell Surface; D000068877:Imatinib Mesylate; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3